ERBB2 and breast carcinoma: Abemaciclib is FDA-approved as a single treatment as well as in combination with fulvestrant or aromatase inhibitors in HR-positive/HER2-negative metastatic or advanced breast cancer treatment with different clinical settings based on results from several clinical trials [18,19,106].